Business
Bausch Health Announces First Quarter 2024 Results
First quarter revenues of $2.15 billion, up 11% on a Reported and 8% on an Organic 1 basis ...
About this update from Bausch Health Companies Inc.
[{"type":"text","content":"Bausch Health Announces First Quarter 2024 ResultsFirst quarter revenues of $2.15 billion, up 11% on a Reported and 8% on an Organic1 basisYear-over-year revenue growth in all segments on both a Reported and Organic1 BasisGAAP Net Loss Attributable to Bausch Health Companies Inc. of $64 MillionAdjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $665 Million, up 13%Xifaxan® Appeal Decision Represents a Significant Milestone related to Full Separation of Bausch + LombReaffirmed full-year Revenue and Adjusted EBITDA (non-GAAP)1 guidanceLAVAL, QC / ACCESSWIRE / May 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (\"Bausch Health\" or the \"Company\" or \"we\" or \"our\") today announced its first quarter 2024 financial results and other key updates from the quarter.\"We are pleased with our strong start to the year, delivering solid first-quarter performance, and our fourth consecutive quarter of year-over-year growth in revenues and adjusted EBITDA. Furthermore, all our business segments posted year-over-year revenue growth on both a reported and organic basis. I'm very proud of what our team has accomplished and we remain focused on continuing our momentum by advancing our R&D pipeline, strengthening our balance sheet and executing on our commercial strategies to drive global growth,\" said Thomas J. Appio, Chief Executive Officer, Bausch Health.\"We are also pleased with other key developments for our business during the quarter, including the appeal decision in the Norwich matter in respect of Xifaxan®, which represents a significant milestone as it relates to achieving the full separation of Bausch + Lomb.\"We will continue to focus on the foundation we set across the enterprise to deliver results and improve the health of patients worldwide,\" continued Mr. Appio.1 This is a non-GAAP measure or a non-GAAP ratio. For further information on non-GAAP measures and non-GAAP ratios, please refer to the \"Non-GAAP Information\" section of this news release. Please also refer to tables at the end of this news release for a reconciliation of this and other non-GAAP measures to the most directly comparable GAAP measure.Bausch Health (excl. B+L) R&D UpdateAmiselimod (S1P modulator): once-daily oral treatment of mild to moderate ulcerative colitisPositive top-line Phase 2 data results a...